JP2009525960A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525960A5 JP2009525960A5 JP2008551297A JP2008551297A JP2009525960A5 JP 2009525960 A5 JP2009525960 A5 JP 2009525960A5 JP 2008551297 A JP2008551297 A JP 2008551297A JP 2008551297 A JP2008551297 A JP 2008551297A JP 2009525960 A5 JP2009525960 A5 JP 2009525960A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- thiazol
- alkyl
- phenyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 74
- -1 thiazolo [5,4-c] pyridinyl Chemical group 0.000 claims 74
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000003118 aryl group Chemical group 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 125000005418 aryl aryl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000005842 heteroatoms Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- RUQPVADMLMMXDR-IBGZPJMESA-N (2S)-1-N-(5-isoquinolin-6-yl-1,3-thiazol-2-yl)-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C=CN=CC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 RUQPVADMLMMXDR-IBGZPJMESA-N 0.000 claims 1
- ONHHLCOLUPUJHO-DEOSSOPVSA-N (2S)-1-N-(5-isoquinolin-6-yl-4-phenyl-1,3-thiazol-2-yl)-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](N)CC=1C=CC(=CC=1)C(F)(F)F)NC(SC=1C=2C=C3C=CN=CC3=CC=2)=NC=1C1=CC=CC=C1 ONHHLCOLUPUJHO-DEOSSOPVSA-N 0.000 claims 1
- PRXJKVDDVOWRHR-SFHVURJKSA-N (2S)-1-N-(5-phthalazin-6-yl-1,3-thiazol-2-yl)-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C=NN=CC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 PRXJKVDDVOWRHR-SFHVURJKSA-N 0.000 claims 1
- VGRYHOBWAAWMSO-NRFANRHFSA-N (2S)-1-N-[4-(furan-2-yl)-5-isoquinolin-6-yl-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](N)CC=1C=CC(=CC=1)C(F)(F)F)NC(SC=1C=2C=C3C=CN=CC3=CC=2)=NC=1C1=CC=CO1 VGRYHOBWAAWMSO-NRFANRHFSA-N 0.000 claims 1
- OTYWCJLDOQPLSL-KRWDZBQOSA-N (2S)-1-N-[4-(methoxymethyl)-5-(1,6-naphthyridin-2-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical class C([C@H](N)CNC1=NC(=C(S1)C=1N=C2C=CN=CC2=CC=1)COC)C1=CC=C(C(F)(F)F)C=C1 OTYWCJLDOQPLSL-KRWDZBQOSA-N 0.000 claims 1
- BOQHAWYNJHNJKM-KRWDZBQOSA-N (2S)-1-N-[4-(methoxymethyl)-5-(3-methyl-2H-indazol-5-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1C=C2C(C)=NNC2=CC=1)COC)C1=CC=C(C(F)(F)F)C=C1 BOQHAWYNJHNJKM-KRWDZBQOSA-N 0.000 claims 1
- WFNHFDUUHUGBIS-FQEVSTJZSA-N (2S)-1-N-[4-(methoxymethyl)-5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]-2-N-(2-morpholin-4-ylethyl)-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC1=NC(=C(S1)C=1SC2=CN=CC=C2N=1)COC)NCCN1CCOCC1)C1=CC=C(C(F)(F)F)C=C1 WFNHFDUUHUGBIS-FQEVSTJZSA-N 0.000 claims 1
- QNPXGYWAPZLUDI-AWEZNQCLSA-N (2S)-1-N-[4-(methoxymethyl)-5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1SC2=CN=CC=C2N=1)COC)C1=CC=C(C(F)(F)F)C=C1 QNPXGYWAPZLUDI-AWEZNQCLSA-N 0.000 claims 1
- IUFSFRMTTMOBER-KRWDZBQOSA-N (2S)-1-N-[4-methyl-5-(3-methyl-2H-indazol-5-yl)-1,3-thiazol-2-yl]-3-phenylpropane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1C=C2C(C)=NNC2=CC=1)C)C1=CC=CC=C1 IUFSFRMTTMOBER-KRWDZBQOSA-N 0.000 claims 1
- KMDQAOCMEQUOAQ-INIZCTEOSA-N (2S)-1-N-[5-(1,6-naphthyridin-2-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1N=C2C=CN=CC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 KMDQAOCMEQUOAQ-INIZCTEOSA-N 0.000 claims 1
- MPLUPNJRXQZQLR-KRWDZBQOSA-N (2S)-1-N-[5-(1H-indazol-5-yl)-4-(methoxymethyl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1C=C2C=NNC2=CC=1)COC)C1=CC=C(C(F)(F)F)C=C1 MPLUPNJRXQZQLR-KRWDZBQOSA-N 0.000 claims 1
- BMLQBUZLVZOSBO-KRWDZBQOSA-N (2S)-1-N-[5-(1H-indazol-5-yl)-4-methyl-1,3-thiazol-2-yl]-3-phenylpropane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1C=C2C=NNC2=CC=1)C)C1=CC=CC=C1 BMLQBUZLVZOSBO-KRWDZBQOSA-N 0.000 claims 1
- SXMJEDMPDDTFKV-INIZCTEOSA-N (2S)-1-N-[5-(1H-indazol-6-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2NN=CC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 SXMJEDMPDDTFKV-INIZCTEOSA-N 0.000 claims 1
- SXZYABNLROKYBA-AWEZNQCLSA-N (2S)-1-N-[5-(3-amino-1,2-benzoxazol-5-yl)-1,3-thiazol-2-yl]-3-(1H-indol-3-yl)propane-1,2-diamine Chemical compound C1=CC=C2C(C[C@@H](CNC=3SC(=CN=3)C=3C=C4C(N)=NOC4=CC=3)N)=CNC2=C1 SXZYABNLROKYBA-AWEZNQCLSA-N 0.000 claims 1
- VWWGPEDOUGDOMJ-AWEZNQCLSA-N (2S)-1-N-[5-(3-amino-1,2-benzoxazol-5-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C(N)=NOC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 VWWGPEDOUGDOMJ-AWEZNQCLSA-N 0.000 claims 1
- HUZSZGBYKRTSEZ-HNNXBMFYSA-N (2S)-1-N-[5-(3-amino-1-methylindazol-6-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC=C(S1)C1=CC=C2C(N)=NN(C2=C1)C)C1=CC=C(C(F)(F)F)C=C1 HUZSZGBYKRTSEZ-HNNXBMFYSA-N 0.000 claims 1
- ZOEZQOZTOFGURN-AWEZNQCLSA-N (2S)-1-N-[5-(3-amino-1H-indazol-5-yl)-1,3-thiazol-2-yl]-3-(1H-indol-3-yl)propane-1,2-diamine Chemical compound C1=CC=C2C(C[C@@H](CNC=3SC(=CN=3)C=3C=C4C(N)=NNC4=CC=3)N)=CNC2=C1 ZOEZQOZTOFGURN-AWEZNQCLSA-N 0.000 claims 1
- FTDNCBJDYUWTID-AWEZNQCLSA-N (2S)-1-N-[5-(3-amino-1H-indazol-5-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C(N)=NNC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 FTDNCBJDYUWTID-AWEZNQCLSA-N 0.000 claims 1
- IEPJGUFCFUXIJJ-AWEZNQCLSA-N (2S)-1-N-[5-(3-amino-1H-indazol-6-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2NN=C(N)C2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 IEPJGUFCFUXIJJ-AWEZNQCLSA-N 0.000 claims 1
- GNXNUXBMLLVKCC-SFHVURJKSA-N (2S)-1-N-[5-(3-aminoisoquinolin-6-yl)-1,3-thiazol-2-yl]-3-(4-chlorophenyl)propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C=C(N)N=CC2=CC=1)N)C1=CC=C(Cl)C=C1 GNXNUXBMLLVKCC-SFHVURJKSA-N 0.000 claims 1
- XLMDNKMMDBSPSJ-SFHVURJKSA-N (2S)-1-N-[5-(3-aminoisoquinolin-6-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C=C(N)N=CC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 XLMDNKMMDBSPSJ-SFHVURJKSA-N 0.000 claims 1
- TYCJPDLIEVIZMC-INIZCTEOSA-N (2S)-1-N-[5-(3-methyl-2H-indazol-5-yl)-1,3-thiazol-2-yl]-3-phenylpropane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC=C(S1)C1=CC=C2NN=C(C2=C1)C)C1=CC=CC=C1 TYCJPDLIEVIZMC-INIZCTEOSA-N 0.000 claims 1
- AWXUWXYPLGCSOO-ZDUSSCGKSA-N (2S)-1-N-[5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]-3-[3-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1SC2=CN=CC=C2N=1)N)C1=CC=CC(C(F)(F)F)=C1 AWXUWXYPLGCSOO-ZDUSSCGKSA-N 0.000 claims 1
- WBWWEGGTYJUJIS-ZDUSSCGKSA-N (2S)-1-N-[5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1SC2=CN=CC=C2N=1)N)C1=CC=C(C(F)(F)F)C=C1 WBWWEGGTYJUJIS-ZDUSSCGKSA-N 0.000 claims 1
- RREBSXDCHJHRDT-FXMQYSIJSA-N (2S)-1-N-[5-isoquinolin-6-yl-4-(1-methoxyethyl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1C=C2C=CN=CC2=CC=1)C(C)OC)C1=CC=C(C(F)(F)F)C=C1 RREBSXDCHJHRDT-FXMQYSIJSA-N 0.000 claims 1
- OZEQEZSPZCUFMW-FQEVSTJZSA-N (2S)-1-N-[5-isoquinolin-6-yl-4-(methoxymethyl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1C=C2C=CN=CC2=CC=1)COC)C1=CC=C(C(F)(F)F)C=C1 OZEQEZSPZCUFMW-FQEVSTJZSA-N 0.000 claims 1
- LVKPDCDJLJWKLG-FQEVSTJZSA-N (2S)-1-N-[5-isoquinolin-6-yl-4-(methylaminomethyl)-1,3-thiazol-2-yl]-3-[4-(trifluoromethyl)phenyl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1C=C2C=CN=CC2=CC=1)CNC)C1=CC=C(C(F)(F)F)C=C1 LVKPDCDJLJWKLG-FQEVSTJZSA-N 0.000 claims 1
- BLAVYYFRUYHSSA-IBGZPJMESA-N (2S)-3-(1H-indol-3-yl)-1-N-(5-isoquinolin-6-yl-1,3-thiazol-2-yl)propane-1,2-diamine Chemical compound C1=CC=C2C(C[C@@H](CNC=3SC(=CN=3)C=3C=C4C=CN=CC4=CC=3)N)=CNC2=C1 BLAVYYFRUYHSSA-IBGZPJMESA-N 0.000 claims 1
- GNUDIMYDTZMJQX-AWEZNQCLSA-N (2S)-3-(1H-indol-3-yl)-1-N-[4-(methoxymethyl)-5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]propane-1,2-diamine Chemical compound C1=NC=C2SC(C=3SC(NC[C@@H](N)CC=4C5=CC=CC=C5NC=4)=NC=3COC)=NC2=C1 GNUDIMYDTZMJQX-AWEZNQCLSA-N 0.000 claims 1
- RUAXRQMFJHIYOD-INIZCTEOSA-N (2S)-3-(1H-indol-3-yl)-1-N-[5-(3-methyl-2H-indazol-5-yl)-1,3-thiazol-2-yl]propane-1,2-diamine Chemical compound C1=CC=C2C(C[C@H](N)CNC3=NC=C(S3)C3=CC=C4NN=C(C4=C3)C)=CNC2=C1 RUAXRQMFJHIYOD-INIZCTEOSA-N 0.000 claims 1
- YYJTVOXCOOYFNN-HNNXBMFYSA-N (2S)-3-(1H-indol-3-yl)-1-N-[5-[3-(methylamino)-1H-indazol-5-yl]-1,3-thiazol-2-yl]propane-1,2-diamine Chemical compound C1=CC=C2C(C[C@H](N)CNC3=NC=C(S3)C3=CC=C4NN=C(C4=C3)NC)=CNC2=C1 YYJTVOXCOOYFNN-HNNXBMFYSA-N 0.000 claims 1
- VGPQUILKMXOHDS-IBGZPJMESA-N (2S)-3-(3-chlorophenyl)-1-N-(5-isoquinolin-6-yl-1,3-thiazol-2-yl)propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C=CN=CC2=CC=1)N)C1=CC=CC(Cl)=C1 VGPQUILKMXOHDS-IBGZPJMESA-N 0.000 claims 1
- SVFHQJXKRMSPEU-AWEZNQCLSA-N (2S)-3-(3-chlorophenyl)-1-N-[4-(methoxymethyl)-5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1SC2=CN=CC=C2N=1)COC)C1=CC=CC(Cl)=C1 SVFHQJXKRMSPEU-AWEZNQCLSA-N 0.000 claims 1
- OLXOCLWPQPPADC-AWEZNQCLSA-N (2S)-3-(3-chlorophenyl)-1-N-[5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-4-(2,2,2-trifluoroethoxymethyl)-1,3-thiazol-2-yl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=C(COCC(F)(F)F)N=1)C=1SC2=CN=CC=C2N=1)N)C1=CC=CC(Cl)=C1 OLXOCLWPQPPADC-AWEZNQCLSA-N 0.000 claims 1
- CSYSTVVLDFRCMG-HNNXBMFYSA-N (2S)-3-(4-chlorophenyl)-1-N-[4-(ethoxymethyl)-5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1SC2=CN=CC=C2N=1)COCC)C1=CC=C(Cl)C=C1 CSYSTVVLDFRCMG-HNNXBMFYSA-N 0.000 claims 1
- AIBWDDHRUDOEOF-AWEZNQCLSA-N (2S)-3-(4-chlorophenyl)-1-N-[4-(methoxymethyl)-5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1SC2=CN=CC=C2N=1)COC)C1=CC=C(Cl)C=C1 AIBWDDHRUDOEOF-AWEZNQCLSA-N 0.000 claims 1
- LJVIDZQPGQAVHM-INIZCTEOSA-N (2S)-3-(4-chlorophenyl)-1-N-[5-(1H-indazol-5-yl)-1,3-thiazol-2-yl]propane-1,2-diamine Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C=NNC2=CC=1)N)C1=CC=C(Cl)C=C1 LJVIDZQPGQAVHM-INIZCTEOSA-N 0.000 claims 1
- XJADBOIGESUADD-INIZCTEOSA-N (2S)-3-(4-chlorophenyl)-1-N-[5-(3-methyl-2H-indazol-5-yl)-1,3-thiazol-2-yl]propane-1,2-diamine Chemical compound C([C@H](N)CNC1=NC=C(S1)C1=CC=C2NN=C(C2=C1)C)C1=CC=C(Cl)C=C1 XJADBOIGESUADD-INIZCTEOSA-N 0.000 claims 1
- LUSRHBIKOIXOAC-AAWXNRKFSA-N (3E)-6-[2-[[(2S)-2-amino-3-(1H-indol-3-yl)propyl]amino]-1,3-thiazol-5-yl]-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one Chemical compound C([C@@H](N)CC=1C2=CC=CC=C2NC=1)NC(S1)=NC=C1C(C=C1NC2=O)=CC=C1\C2=C/C1=CN=CN1 LUSRHBIKOIXOAC-AAWXNRKFSA-N 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- AQFCZZTXQHWYBA-INIZCTEOSA-N 2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-5-(2-oxo-1,3-dihydroindol-5-yl)-1,3-thiazole-4-carbonitrile Chemical compound C([C@@H](CNC=1SC(=C(C#N)N=1)C=1C=C2CC(=O)NC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 AQFCZZTXQHWYBA-INIZCTEOSA-N 0.000 claims 1
- WFKTZAHDPJCVKI-HNNXBMFYSA-N 2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-5-(3-methyl-2-oxo-1H-benzimidazol-5-yl)-1,3-thiazole-4-carbonitrile Chemical compound C([C@H](N)CNC=1SC(=C(N=1)C#N)C=1C=C2N(C(NC2=CC=1)=O)C)C1=CC=C(C(F)(F)F)C=C1 WFKTZAHDPJCVKI-HNNXBMFYSA-N 0.000 claims 1
- YPVHGNDNIRSOLV-IBGZPJMESA-N 2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-5-isoquinolin-6-yl-1,3-thiazole-4-carbonitrile Chemical compound C([C@@H](CNC=1SC(=C(C#N)N=1)C=1C=C2C=CN=CC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 YPVHGNDNIRSOLV-IBGZPJMESA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- GTLIIZSSDYQHLI-INIZCTEOSA-N 5-[2-[[(2S)-2-amino-3-(1H-indol-3-yl)propyl]amino]-1,3-thiazol-5-yl]-1,3-dihydroindol-2-one Chemical compound C1=CC=C2C(C[C@@H](CNC=3SC(=CN=3)C=3C=C4CC(=O)NC4=CC=3)N)=CNC2=C1 GTLIIZSSDYQHLI-INIZCTEOSA-N 0.000 claims 1
- WNUCYWQQQOPMBN-INIZCTEOSA-N 5-[2-[[(2S)-2-amino-3-(4-chlorophenyl)propyl]amino]-1,3-thiazol-5-yl]-1,3-dihydroindol-2-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2CC(=O)NC2=CC=1)N)C1=CC=C(Cl)C=C1 WNUCYWQQQOPMBN-INIZCTEOSA-N 0.000 claims 1
- IRSCVIJZBTUXFN-INIZCTEOSA-N 5-[2-[[(2S)-2-amino-3-(4-methoxyphenyl)propyl]amino]-1,3-thiazol-5-yl]-1,3-dihydroindol-2-one Chemical compound C1=CC(OC)=CC=C1C[C@H](N)CNC1=NC=C(C=2C=C3CC(=O)NC3=CC=2)S1 IRSCVIJZBTUXFN-INIZCTEOSA-N 0.000 claims 1
- XGNAWINLKHSMKO-INIZCTEOSA-N 5-[2-[[(2S)-2-amino-3-[3-(trifluoromethyl)phenyl]propyl]amino]-1,3-thiazol-5-yl]-1,3-dihydroindol-2-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2CC(=O)NC2=CC=1)N)C1=CC=CC(C(F)(F)F)=C1 XGNAWINLKHSMKO-INIZCTEOSA-N 0.000 claims 1
- XPPKIHZJFAAJLB-INIZCTEOSA-N 5-[2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-1,3-thiazol-5-yl]-1,3-dihydroindol-2-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2CC(=O)NC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 XPPKIHZJFAAJLB-INIZCTEOSA-N 0.000 claims 1
- RTDOHUVRLULWIP-AWEZNQCLSA-N 5-[2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-1,3-thiazol-5-yl]-3,3-difluoro-1H-indol-2-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C(F)(F)C(=O)NC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 RTDOHUVRLULWIP-AWEZNQCLSA-N 0.000 claims 1
- LQVQTIBGYOCLJB-INSVYWFGSA-N 5-[2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-1,3-thiazol-5-yl]-3-methyl-1,3-dihydroindol-2-one Chemical compound C([C@H](N)CNC1=NC=C(S1)C1=CC=C2NC(=O)C(C2=C1)C)C1=CC=C(C(F)(F)F)C=C1 LQVQTIBGYOCLJB-INSVYWFGSA-N 0.000 claims 1
- KFPXMNDLAVILED-KRWDZBQOSA-N 5-[2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-4-(methoxymethyl)-1,3-thiazol-5-yl]-1,3-dihydroindol-2-one Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1C=C2CC(=O)NC2=CC=1)COC)C1=CC=C(C(F)(F)F)C=C1 KFPXMNDLAVILED-KRWDZBQOSA-N 0.000 claims 1
- LEICLQSPUKYOCA-INIZCTEOSA-N 5-[2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-4-(methoxymethyl)-1,3-thiazol-5-yl]-3-methyl-1H-benzimidazol-2-one Chemical compound C([C@H](N)CNC1=NC(=C(S1)C=1C=C2N(C)C(=O)NC2=CC=1)COC)C1=CC=C(C(F)(F)F)C=C1 LEICLQSPUKYOCA-INIZCTEOSA-N 0.000 claims 1
- WMFQVXIDVPQEPP-VYIIXAMBSA-N 5-[2-[[(2S)-2-amino-3-phenylpropyl]amino]-1,3-thiazol-5-yl]-3-methyl-1,3-dihydroindol-2-one Chemical compound C([C@H](N)CNC1=NC=C(S1)C1=CC=C2NC(=O)C(C2=C1)C)C1=CC=CC=C1 WMFQVXIDVPQEPP-VYIIXAMBSA-N 0.000 claims 1
- XXIWNSJANUWTAF-AWEZNQCLSA-N 6-[2-[[(2S)-2-amino-3-(1H-indol-3-yl)propyl]amino]-1,3-thiazol-5-yl]-3H-1,3-benzothiazol-2-one Chemical compound C1=CC=C2C(C[C@@H](CNC=3SC(=CN=3)C=3C=C4SC(=O)NC4=CC=3)N)=CNC2=C1 XXIWNSJANUWTAF-AWEZNQCLSA-N 0.000 claims 1
- CELYFJOYJNTTEV-AWEZNQCLSA-N 6-[2-[[(2S)-2-amino-3-(1H-indol-3-yl)propyl]amino]-1,3-thiazol-5-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(C[C@@H](CNC=3SC(=CN=3)C=3C=C4OC(=O)NC4=CC=3)N)=CNC2=C1 CELYFJOYJNTTEV-AWEZNQCLSA-N 0.000 claims 1
- HBAJEILBHKIJBU-AWEZNQCLSA-N 6-[2-[[(2S)-2-amino-3-(4-chlorophenyl)propyl]amino]-1,3-thiazol-5-yl]-3H-1,3-benzoxazol-2-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2OC(=O)NC2=CC=1)N)C1=CC=C(Cl)C=C1 HBAJEILBHKIJBU-AWEZNQCLSA-N 0.000 claims 1
- FNQWGQWNXGGAFV-AWEZNQCLSA-N 6-[2-[[(2S)-2-amino-3-(4-methoxyphenyl)propyl]amino]-1,3-thiazol-5-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1=CC(OC)=CC=C1C[C@H](N)CNC1=NC=C(C=2C=C3OC(=O)NC3=CC=2)S1 FNQWGQWNXGGAFV-AWEZNQCLSA-N 0.000 claims 1
- OQSWTHOOFMVYCO-AWEZNQCLSA-N 6-[2-[[(2S)-2-amino-3-[3-(trifluoromethyl)phenyl]propyl]amino]-1,3-thiazol-5-yl]-3H-1,3-benzoxazol-2-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2OC(=O)NC2=CC=1)N)C1=CC=CC(C(F)(F)F)=C1 OQSWTHOOFMVYCO-AWEZNQCLSA-N 0.000 claims 1
- GYYKIZSJNOKDNA-INIZCTEOSA-N 6-[2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-1,3-thiazol-5-yl]-2H-phthalazin-1-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2C=NN=C(O)C2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 GYYKIZSJNOKDNA-INIZCTEOSA-N 0.000 claims 1
- JDMVDVWEHDEPEM-KRWDZBQOSA-N 6-[2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-1,3-thiazol-5-yl]-3,4-dihydro-1H-quinolin-2-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2CCC(=O)NC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 JDMVDVWEHDEPEM-KRWDZBQOSA-N 0.000 claims 1
- ACASJCMNZMOGPH-AWEZNQCLSA-N 6-[2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-1,3-thiazol-5-yl]-3H-1,3-benzothiazol-2-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2SC(=O)NC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 ACASJCMNZMOGPH-AWEZNQCLSA-N 0.000 claims 1
- NIKDKNHGEBMTNT-AWEZNQCLSA-N 6-[2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-1,3-thiazol-5-yl]-3H-1,3-benzoxazol-2-one Chemical compound C([C@@H](CNC=1SC(=CN=1)C=1C=C2OC(=O)NC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 NIKDKNHGEBMTNT-AWEZNQCLSA-N 0.000 claims 1
- WQSTWAQVOOWIDI-INIZCTEOSA-N N-[(2S)-2-amino-3-(3-chlorophenyl)propyl]-N-[4-(methoxymethyl)-5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]acetamide Chemical compound C([C@H](N)CN(C1=NC(=C(S1)C=1SC2=CN=CC=C2N=1)COC)C(C)=O)C1=CC=CC(Cl)=C1 WQSTWAQVOOWIDI-INIZCTEOSA-N 0.000 claims 1
- RICPXEDFSOVZEH-QFIPXVFZSA-N N-[4-(methoxymethyl)-5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-yl]-N-[(2S)-2-(2-morpholin-4-ylethylamino)-3-[4-(trifluoromethyl)phenyl]propyl]acetamide Chemical compound C([C@@H](CN(C1=NC(=C(S1)C=1SC2=CN=CC=C2N=1)COC)C(C)=O)NCCN1CCOCC1)C1=CC=C(C(F)(F)F)C=C1 RICPXEDFSOVZEH-QFIPXVFZSA-N 0.000 claims 1
- GRJXJQVWAGDYOT-UHFFFAOYSA-N N-benzyl-5-([1,3]thiazolo[5,4-c]pyridin-2-yl)-1,3-thiazol-2-amine Chemical compound N=1C=C(C=2SC3=CN=CC=C3N=2)SC=1NCC1=CC=CC=C1 GRJXJQVWAGDYOT-UHFFFAOYSA-N 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 241001135917 Vitellaria paradoxa Species 0.000 claims 1
- UVFXPMPINVJLQC-INIZCTEOSA-N [2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-5-(1H-indazol-5-yl)-1,3-thiazol-4-yl]methanol Chemical compound C([C@@H](CNC=1SC(=C(CO)N=1)C=1C=C2C=NNC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 UVFXPMPINVJLQC-INIZCTEOSA-N 0.000 claims 1
- LCTODEYEWLOXRB-INIZCTEOSA-N [2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-5-(3-methyl-2H-indazol-5-yl)-1,3-thiazol-4-yl]methanol Chemical compound C([C@H](N)CNC=1SC(=C(N=1)CO)C1=CC=C2NN=C(C2=C1)C)C1=CC=C(C(F)(F)F)C=C1 LCTODEYEWLOXRB-INIZCTEOSA-N 0.000 claims 1
- QDYCTALEGOKETB-IBGZPJMESA-N [2-[[(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl]amino]-5-isoquinolin-6-yl-1,3-thiazol-4-yl]methanol Chemical compound C([C@@H](CNC=1SC(=C(CO)N=1)C=1C=C2C=CN=CC2=CC=1)N)C1=CC=C(C(F)(F)F)C=C1 QDYCTALEGOKETB-IBGZPJMESA-N 0.000 claims 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004965 chloroalkyl group Chemical group 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75954606P | 2006-01-18 | 2006-01-18 | |
US60/759,546 | 2006-01-18 | ||
PCT/US2007/000871 WO2007084391A2 (en) | 2006-01-18 | 2007-01-11 | Thiazole compounds as protein kinase b ( pkb) inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009525960A JP2009525960A (ja) | 2009-07-16 |
JP2009525960A5 true JP2009525960A5 (US08084479-20111227-C00115.png) | 2010-01-21 |
JP5199885B2 JP5199885B2 (ja) | 2013-05-15 |
Family
ID=38180602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008551297A Expired - Fee Related JP5199885B2 (ja) | 2006-01-18 | 2007-01-11 | プロテインキナーゼb(pkb)阻害剤としてのチアゾール化合物 |
Country Status (21)
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007004551A (es) * | 2004-10-18 | 2007-05-23 | Amgen Inc | Compuestos tiadiazol y metodos de uso. |
US7514566B2 (en) * | 2006-01-18 | 2009-04-07 | Amgen, Inc. | Thiazole compounds and methods of use |
CA2678036A1 (en) | 2007-02-13 | 2008-08-21 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
AU2008276512A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
JP2010533715A (ja) * | 2007-07-17 | 2010-10-28 | アムジエン・インコーポレーテツド | 複素環系pkb調節剤 |
UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
US20110092423A1 (en) * | 2008-06-26 | 2011-04-21 | GlaxoSmithKline, LLC | INHIBITORS OF Akt ACTIVITY |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
MX2011001872A (es) * | 2008-08-18 | 2011-05-23 | Univ Yale | Moduladores de mif. |
CN106243100B (zh) * | 2008-10-10 | 2019-04-09 | Vm生物医药公司 | 治疗酒精使用障碍,疼痛和其他疾病的药物组合与方法 |
JP5770102B2 (ja) * | 2008-12-19 | 2015-08-26 | ジェネンテック, インコーポレイテッド | 複素環化合物と使用方法 |
US20110263647A1 (en) * | 2009-01-15 | 2011-10-27 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
EP2440556A1 (en) * | 2009-06-10 | 2012-04-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
EP3309151A1 (en) * | 2009-06-25 | 2018-04-18 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
US8835450B2 (en) | 2009-10-08 | 2014-09-16 | Glaxosmithkline Llc | Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer |
KR101696003B1 (ko) * | 2009-10-08 | 2017-01-13 | 노파르티스 아게 | 조합물 |
JP2013507442A (ja) * | 2009-10-12 | 2013-03-04 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
CN105801550B (zh) | 2009-11-05 | 2019-06-14 | 理森制药股份公司 | 新型苯并吡喃激酶调节剂 |
WO2011115071A1 (ja) * | 2010-03-15 | 2011-09-22 | 国立大学法人広島大学 | チエノピリジン誘導体及びその製造方法、並びにそれを用いた有機半導体デバイス |
JP5578705B2 (ja) * | 2010-03-29 | 2014-08-27 | 公益財団法人相模中央化学研究所 | (アリール)ジフルオロ酢酸エステル誘導体及びその製造方法 |
JP2013525303A (ja) * | 2010-04-16 | 2013-06-20 | アッヴィ・インコーポレイテッド | フタラジン−(2h)−オン系キナーゼ阻害薬 |
WO2011133733A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
WO2011130921A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
EA024842B9 (ru) | 2011-05-04 | 2017-08-31 | Ризен Фармасьютикалз Са | Соединения в качестве модуляторов протеинкиназы pi3k |
WO2013049250A1 (en) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
CN103304468A (zh) * | 2012-03-13 | 2013-09-18 | 华东师范大学 | 一种氧化吲哚的一锅法串联合成方法 |
WO2013146754A1 (ja) | 2012-03-27 | 2013-10-03 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素5員環誘導体 |
WO2013173382A1 (en) | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein |
MX357043B (es) | 2012-07-04 | 2018-06-25 | Rhizen Pharmaceuticals Sa | Inhibidores selectivos de pi3k delta. |
US20160002185A1 (en) | 2013-02-19 | 2016-01-07 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
RU2015143526A (ru) * | 2013-03-13 | 2017-04-19 | Бостон Байомедикал, Инк. | Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака |
AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
MX2016006025A (es) | 2013-11-11 | 2016-12-02 | Amgen Inc | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. |
EP3265454B1 (en) * | 2015-03-02 | 2020-02-26 | Rigel Pharmaceuticals, Inc. | Tgf-beta inhibitors |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
JP6893520B2 (ja) * | 2016-03-10 | 2021-06-23 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | ホスファチジルイノシトール3−キナーゼガンマの新規の阻害剤 |
JP7129420B6 (ja) | 2017-03-30 | 2024-02-02 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Hpk1阻害剤としてのイソキノリン |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
HRP20221196T1 (hr) | 2017-10-05 | 2022-12-09 | Fulcrum Therapeutics, Inc. | Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
AU2019230014A1 (en) | 2018-03-05 | 2020-09-17 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
US20220372018A1 (en) * | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
WO2021126816A1 (en) | 2019-12-16 | 2021-06-24 | Amgen Inc. | Dosing regimen of a kras g12c inhibitor |
CN111603466B (zh) * | 2020-06-29 | 2022-07-22 | 江南大学 | 一种乙酮类化合物在制备治疗肿瘤药物中的应用 |
CN114014787B (zh) * | 2022-01-10 | 2022-03-22 | 苏州开元民生科技股份有限公司 | 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法 |
CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3591600A (en) | 1969-07-07 | 1971-07-06 | Stauffer Chemical Co | 2-aminothiazole phosphates and phosphonates |
GB1435139A (en) | 1972-08-17 | 1976-05-12 | Sumitomo Chemical Co | Thiazole derivatives |
JPS5239827B2 (US08084479-20111227-C00115.png) | 1973-11-08 | 1977-10-07 | ||
US4086239A (en) | 1977-07-01 | 1978-04-25 | Stauffer Chemical Company | Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods |
DK150068C (da) | 1978-06-02 | 1987-06-29 | Pfizer | Analogifremgangsmaade til fremstilling af aminothiazoler |
US4297365A (en) * | 1978-08-04 | 1981-10-27 | Ciba-Geigy Corporation | Benzimidazoles and pharmaceutical preparations containing such compounds |
US4451471A (en) | 1981-03-18 | 1984-05-29 | Ciba-Geigy Corporation | Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same |
FR2511375A1 (fr) | 1981-08-17 | 1983-02-18 | Rhone Poulenc Sante | Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent |
DE3630732A1 (de) | 1986-09-10 | 1988-03-17 | Bayer Ag | 2-cyano-2-alkoximino-acetamide |
US5232921A (en) * | 1987-03-12 | 1993-08-03 | Sanofi | Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions |
JPH0753666B2 (ja) | 1987-09-14 | 1995-06-07 | 久光製薬株式会社 | 置換ジフェニルチアゾール誘導体からなる抗炎症剤 |
FR2636628B1 (fr) | 1988-08-25 | 1990-12-28 | Sanofi Sa | Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant |
US5302608A (en) | 1988-11-18 | 1994-04-12 | Takeda Chemical Industries, Ltd. | Age formation inhibitors |
US5145860A (en) | 1989-01-05 | 1992-09-08 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole compounds and pharmaceutical composition comprising the same |
US5550138A (en) | 1992-03-25 | 1996-08-27 | Takeda Chemical Industries, Ltd. | Condensed thiadiazole derivative, method of its production, and use thereof |
CA2206315A1 (en) | 1994-11-29 | 1996-06-06 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
FR2735777B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
US6407124B1 (en) | 1998-06-18 | 2002-06-18 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
JP2002518380A (ja) | 1998-06-18 | 2002-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤 |
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
AU3487500A (en) | 1999-02-08 | 2000-08-25 | Lion Bioscience Ag | Thiazole derivatives and combinatorial libraries thereof |
AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
WO2001010865A1 (fr) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | INHIBITEURS DE p38MAP KINASE |
JP2001114690A (ja) * | 1999-08-06 | 2001-04-24 | Takeda Chem Ind Ltd | p38MAPキナーゼ阻害剤 |
AU2001244618A1 (en) | 2000-03-30 | 2001-10-15 | Takeda Chemical Industries Ltd. | Substituted 1,3-thiazole compounds, their production and use |
US6586453B2 (en) | 2000-04-03 | 2003-07-01 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
US7074934B2 (en) | 2000-06-13 | 2006-07-11 | Tularik Limited | Serine protease inhibitors |
GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
JP4689801B2 (ja) | 2000-08-09 | 2011-05-25 | ケミプロ化成株式会社 | アミノチアゾール誘導体の製造方法 |
JP2002053566A (ja) | 2000-08-11 | 2002-02-19 | Japan Tobacco Inc | チアゾール化合物及びその医薬用途 |
GB0114185D0 (en) | 2001-06-12 | 2001-08-01 | Protherics Molecular Design Lt | Compounds |
US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
AR032653A1 (es) | 2001-02-09 | 2003-11-19 | Telik Inc | Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos. |
ES2254611T3 (es) * | 2001-05-11 | 2006-06-16 | Pfizer Products Inc. | Derivados de tiazol. |
EP1402900A1 (en) | 2001-06-11 | 2004-03-31 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
AR039059A1 (es) | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
CA2460909A1 (en) * | 2001-09-28 | 2003-04-10 | Cyclacel Limited | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds |
GB0123589D0 (en) | 2001-10-01 | 2001-11-21 | Syngenta Participations Ag | Organic compounds |
JP2005510508A (ja) | 2001-11-08 | 2005-04-21 | 藤沢薬品工業株式会社 | アデノシンアンタゴニストとしてのチアゾールピリダジノン類 |
JP2005526720A (ja) | 2002-02-13 | 2005-09-08 | ファーマジーン ラボラトリーズ リミテッド | 5−ht2b受容体アンタゴニスト |
TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
WO2003072577A1 (en) | 2002-02-28 | 2003-09-04 | F.Hoffmann-La Roche Ag | Thiazole derivatives as npy receptor antagonists |
US20040053948A1 (en) | 2002-05-10 | 2004-03-18 | Cytokinetics, Inc. | Compounds, compositions and methods |
FR2842523A1 (fr) | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
EP1551815A1 (en) | 2002-10-09 | 2005-07-13 | Pfizer Products Inc. | Thiazole compounds for the treatment of neurodegenerative disorders |
DE60332475D1 (de) | 2002-10-30 | 2010-06-17 | Vertex Pharma | Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen |
GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
FR2850380B1 (fr) | 2003-01-23 | 2006-07-07 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique |
JP2006182648A (ja) | 2003-04-08 | 2006-07-13 | Dai Ichi Seiyaku Co Ltd | 7員複素環誘導体 |
TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
JP2007512230A (ja) | 2003-08-20 | 2007-05-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用な(4−アミノ−1,2,5−オキサジアゾール−4−イル)−ヘテロ芳香族化合物 |
ZA200602755B (en) | 2003-09-06 | 2007-06-27 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
GB0329275D0 (en) | 2003-12-18 | 2004-01-21 | Merck Sharp & Dohme | Therapeutic treatment |
BRPI0506749A (pt) | 2004-01-12 | 2007-05-22 | Applied Research Systems | derivados de tiazol e uso dos mesmos |
JP4813371B2 (ja) | 2004-01-16 | 2011-11-09 | サノフイ−アベンテイス | アシルアミノチアゾール誘導体及びβ−アミロイド阻害剤としてのこれらの使用 |
RU2401262C2 (ru) | 2004-01-16 | 2010-10-10 | Санофи-Авентис | Производные алкиламинотиазола, их получение и их применение в терапии |
EP1720855A4 (en) * | 2004-03-02 | 2008-12-17 | Smithkline Beecham Corp | HEMMER OF ACT ACTIVITY |
GEP20084420B (en) | 2004-03-23 | 2008-07-10 | Pfizer Prod Inc | Use of imidazole compounds for the treatment of neurodegenerative disorders |
US7470701B2 (en) | 2004-03-30 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Substituted 2,5-heterocyclic derivatives |
AU2005247871A1 (en) * | 2004-04-27 | 2005-12-08 | Research Development Foundation | Antagonism of TGF-beta superfamily receptor signaling |
CA2571828A1 (en) | 2004-05-21 | 2005-12-01 | Mpex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors and methods of treating bacterial infections |
GB0411791D0 (en) | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
ES2401138T3 (es) | 2004-08-13 | 2013-04-17 | Genentech, Inc. | Inhibidores basados en tiazol de enzimas que usan ATP |
WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
MX2007004551A (es) * | 2004-10-18 | 2007-05-23 | Amgen Inc | Compuestos tiadiazol y metodos de uso. |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
US20060178388A1 (en) | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
KR100917511B1 (ko) | 2005-02-28 | 2009-09-16 | 니뽄 다바코 산교 가부시키가이샤 | Syk 저해 활성을 갖는 신규한 아미노피리딘 화합물 |
KR101386282B1 (ko) | 2005-06-17 | 2014-04-17 | 아포지 바이오테크놀로지 코포레이션 | 스핑고신 키나제 저해제 |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
DE102005048072A1 (de) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
US7871982B2 (en) | 2005-12-09 | 2011-01-18 | Meiji Seika Kaisha, Ltd. | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient |
CA2633569A1 (en) | 2005-12-12 | 2007-06-21 | Genelabs Technologies, Inc. | N-(5-membered heteroaromatic ring)-amido anti-viral compounds |
WO2007082805A1 (en) | 2006-01-18 | 2007-07-26 | F. Hoffmann-La Roche Ag | Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors |
US7514566B2 (en) | 2006-01-18 | 2009-04-07 | Amgen, Inc. | Thiazole compounds and methods of use |
KR20080097426A (ko) | 2006-01-18 | 2008-11-05 | 쉐링 코포레이션 | 칸나비노이드 수용체 조절제 |
US20080242694A1 (en) | 2006-09-18 | 2008-10-02 | D Sidocky Neil R | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith |
-
2007
- 2007-01-11 US US11/652,728 patent/US7514566B2/en active Active
- 2007-01-11 JP JP2008551297A patent/JP5199885B2/ja not_active Expired - Fee Related
- 2007-01-11 AU AU2007207743A patent/AU2007207743B2/en not_active Ceased
- 2007-01-11 CN CNA2007800097081A patent/CN101421265A/zh active Pending
- 2007-01-11 EA EA200801716A patent/EA200801716A1/ru unknown
- 2007-01-11 ES ES07718125T patent/ES2389062T3/es active Active
- 2007-01-11 EP EP07718125A patent/EP1981884B1/en active Active
- 2007-01-11 BR BRPI0706621-0A patent/BRPI0706621A2/pt not_active IP Right Cessation
- 2007-01-11 CA CA2636077A patent/CA2636077C/en not_active Expired - Fee Related
- 2007-01-11 KR KR1020087019941A patent/KR20080091369A/ko not_active Application Discontinuation
- 2007-01-11 WO PCT/US2007/000871 patent/WO2007084391A2/en active Application Filing
- 2007-01-11 MY MYPI20082598A patent/MY149143A/en unknown
- 2007-01-17 TW TW096101796A patent/TW200738657A/zh unknown
- 2007-01-18 UY UY30098A patent/UY30098A1/es not_active Application Discontinuation
- 2007-01-18 AR ARP070100212A patent/AR059064A1/es unknown
- 2007-01-18 PE PE2007000057A patent/PE20071114A1/es not_active Application Discontinuation
- 2007-11-01 UA UAA200810455A patent/UA91895C2/ru unknown
-
2008
- 2008-07-10 IL IL192751A patent/IL192751A0/en unknown
- 2008-07-23 ZA ZA200806386A patent/ZA200806386B/xx unknown
- 2008-08-18 CR CR10211A patent/CR10211A/es not_active Application Discontinuation
- 2008-08-18 NO NO20083572A patent/NO20083572L/no not_active Application Discontinuation
-
2009
- 2009-02-11 US US12/378,195 patent/US8084479B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009525960A5 (US08084479-20111227-C00115.png) | ||
CA2636077A1 (en) | Thiazole compounds as protein kinase b (pkb) inhibitors | |
US7495018B2 (en) | Substituted 1,3-thiazole compounds, their production and use | |
TWI222447B (en) | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | |
KR101389246B1 (ko) | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 | |
AU2007351498B2 (en) | Organic compounds | |
JP5412429B2 (ja) | 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物 | |
JP2007500253A5 (US08084479-20111227-C00115.png) | ||
JP2008516986A5 (US08084479-20111227-C00115.png) | ||
RU2492167C2 (ru) | Производные аминотриазола в качестве агонистов alх | |
CA2583217A1 (en) | 1,3,4-thiadiazole compounds as protein kinase inhibitors | |
JP2010533715A5 (US08084479-20111227-C00115.png) | ||
JP2007516173A5 (US08084479-20111227-C00115.png) | ||
JP2005527625A5 (US08084479-20111227-C00115.png) | ||
AU2014291142A1 (en) | Cyanotriazole compounds | |
US20150057271A1 (en) | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors | |
JP2004531473A (ja) | N−ピリジルカルボキサミド誘導体及びそれらを含有する医薬組成物 | |
ZA200300886B (en) | Indazole derivatives as JNK inhibitors. | |
JP2008509982A5 (US08084479-20111227-C00115.png) | ||
RU2007107177A (ru) | Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов | |
CA2603826A1 (en) | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors | |
JP2010540462A5 (US08084479-20111227-C00115.png) | ||
RU2016111138A (ru) | Гетероциклические соединения и способы их применения | |
JP2013517279A5 (US08084479-20111227-C00115.png) | ||
JP2016523963A5 (US08084479-20111227-C00115.png) |